A review of kallikrein inhibitor lanadelumab in hereditary angioedema

Gloria Hwang, Ansh Johri, Sally Ng, Timothy Craig

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hereditary angioedema with C1 esterase inhibitor deficiency is a rare disorder characterized by unpredictable swelling of the face, larynx and gastrointestinal tract. Kallikreins are serine proteases that cleave kininogens to produce bradykinin leading to inflammation. A new prophylactic drug is lanadelumab (DX-2930, SHP-643), a recombinant, fully human IgG1 monoclonal antibody kallikrein inhibitor. Pharmacokinetics show a half-life of 14 days with a dose-dependent effect. Completed trials for lanadelumab include two Phase III studies with updated efficacy in preventing angioedema in hereditary angioedema patients. Ongoing data show the safety of the targeted therapy along with less frequent administration requirements. Information on long-term safety is still needed, as well as, further studies on the correlation of subcutaneous administered dosing requirements and severity of side effects.

Original languageEnglish (US)
Pages (from-to)937-943
Number of pages7
JournalImmunotherapy
Volume11
Issue number11
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hereditary Angioedemas
Kallikreins
Kininogens
Safety
Angioedema
Serine Proteases
Bradykinin
Larynx
Half-Life
Gastrointestinal Tract
Pharmacokinetics
Immunoglobulin G
Monoclonal Antibodies
Inflammation
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Hwang, Gloria ; Johri, Ansh ; Ng, Sally ; Craig, Timothy. / A review of kallikrein inhibitor lanadelumab in hereditary angioedema. In: Immunotherapy. 2019 ; Vol. 11, No. 11. pp. 937-943.
@article{6109d1b136be42d0b8a45f5f0cf8c430,
title = "A review of kallikrein inhibitor lanadelumab in hereditary angioedema",
abstract = "Hereditary angioedema with C1 esterase inhibitor deficiency is a rare disorder characterized by unpredictable swelling of the face, larynx and gastrointestinal tract. Kallikreins are serine proteases that cleave kininogens to produce bradykinin leading to inflammation. A new prophylactic drug is lanadelumab (DX-2930, SHP-643), a recombinant, fully human IgG1 monoclonal antibody kallikrein inhibitor. Pharmacokinetics show a half-life of 14 days with a dose-dependent effect. Completed trials for lanadelumab include two Phase III studies with updated efficacy in preventing angioedema in hereditary angioedema patients. Ongoing data show the safety of the targeted therapy along with less frequent administration requirements. Information on long-term safety is still needed, as well as, further studies on the correlation of subcutaneous administered dosing requirements and severity of side effects.",
author = "Gloria Hwang and Ansh Johri and Sally Ng and Timothy Craig",
year = "2019",
month = "1",
day = "1",
doi = "10.2217/imt-2018-0197",
language = "English (US)",
volume = "11",
pages = "937--943",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "11",

}

A review of kallikrein inhibitor lanadelumab in hereditary angioedema. / Hwang, Gloria; Johri, Ansh; Ng, Sally; Craig, Timothy.

In: Immunotherapy, Vol. 11, No. 11, 01.01.2019, p. 937-943.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A review of kallikrein inhibitor lanadelumab in hereditary angioedema

AU - Hwang, Gloria

AU - Johri, Ansh

AU - Ng, Sally

AU - Craig, Timothy

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Hereditary angioedema with C1 esterase inhibitor deficiency is a rare disorder characterized by unpredictable swelling of the face, larynx and gastrointestinal tract. Kallikreins are serine proteases that cleave kininogens to produce bradykinin leading to inflammation. A new prophylactic drug is lanadelumab (DX-2930, SHP-643), a recombinant, fully human IgG1 monoclonal antibody kallikrein inhibitor. Pharmacokinetics show a half-life of 14 days with a dose-dependent effect. Completed trials for lanadelumab include two Phase III studies with updated efficacy in preventing angioedema in hereditary angioedema patients. Ongoing data show the safety of the targeted therapy along with less frequent administration requirements. Information on long-term safety is still needed, as well as, further studies on the correlation of subcutaneous administered dosing requirements and severity of side effects.

AB - Hereditary angioedema with C1 esterase inhibitor deficiency is a rare disorder characterized by unpredictable swelling of the face, larynx and gastrointestinal tract. Kallikreins are serine proteases that cleave kininogens to produce bradykinin leading to inflammation. A new prophylactic drug is lanadelumab (DX-2930, SHP-643), a recombinant, fully human IgG1 monoclonal antibody kallikrein inhibitor. Pharmacokinetics show a half-life of 14 days with a dose-dependent effect. Completed trials for lanadelumab include two Phase III studies with updated efficacy in preventing angioedema in hereditary angioedema patients. Ongoing data show the safety of the targeted therapy along with less frequent administration requirements. Information on long-term safety is still needed, as well as, further studies on the correlation of subcutaneous administered dosing requirements and severity of side effects.

UR - http://www.scopus.com/inward/record.url?scp=85068154006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068154006&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0197

DO - 10.2217/imt-2018-0197

M3 - Article

C2 - 31234673

AN - SCOPUS:85068154006

VL - 11

SP - 937

EP - 943

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 11

ER -